Cytokine antagonists for the treatment of localized disorders
OwnerEdward L. Tobinickinventor
Life of this patent
Estimating the term…
Abstract
Cytokine antagonists for use in localized clinical disorders are provided for the treatment and prevention of damage to the optic nerve, other cranial nerves, spinal cord, nerve roots, peripheral nerves or muscles caused by any one of the following: a herniated nucleus pulposus, osteoarthritis, other forms of arthritis, disorders of bone, disease, or trauma. The cytokine antagonists are used to treat these disorders by local administration. These cytokine antagonists include antagonists to tumor necrosis factor; interleukin-1; interleukin-6; and interleukin-8.
Claims38
A method for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human, comprising the steps of:
- a) administering a therapeutically effective dosage level to said human of said TNF antagonist selected from the group consisting of a fusion protein identified as etanercept, infliximab, CDP571 (a humanized monoclonal anti-TNF-alpha IgG4 antibody), CDP 870 (a humanized monoclonal anti-TNF-alpha antibody fragment) and D2E7 (a human anti-TNF mAb) for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human;
- and
- b) administering said dose either intralesionally or perilesionally.
A method for inhibiting the action of TNF for treating or preventing nerve root injury in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue of said nerve root of said human, or for modulating the immune response affecting neuronal tissue of said nerve root of said human, comprising the steps of:
- a) administering a therapeutically effective dosage level to said human of etanercept, for reducing the inflammation of said nerve root of said human, or for modulating the immune response affecting neuronal tissue of said human;
- and
- b) administering said dose either intralesionally or perilesionally.
A method for inhibiting the action of TNF for treating or preventing nerve root injury in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue of said nerve root of said human, or for modulating the immune response affecting neuronal tissue of said nerve root of said human, comprising the steps of:
- a) administering a therapeutically effective dosage level to said human of etanercept, for reducing the inflammation of said nerve root of said human, or for modulating the immune response affecting neuronal tissue of said human;
- and
- b) administering said dose subcutaneously to the area anatomically adjacent to the site of disc herniation.
A method for inhibiting the action of TNF for treating or preventing nerve root injury in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue of said nerve root of said human, or for modulating the immune response affecting neuronal tissue of said nerve root of said human, comprising the steps of:
- a) administering a therapeutically effective dosage level to said human of said TNF antagonist selected from the group consisting of etanercept, infliximab, CDP571 (a humanized monoclonal anti-TNF-alpha IgG4 antibody), CDP 870 (a humanized monoclonal anti-TNF-alpha antibody fragment) and D2E7 (a human anti-TNF mAb), for reducing the inflammation of said nerve root of said human, or for modulating the immune response affecting neuronal tissue of said human;
- and
- b) administering said dose either intralesionally or perilesionally.
A method for inhibiting the action of TNF for treating glaucoma in a human by administering a TNF antagonist for reducing the inflammation of the optic nerve or retina of said human, or for modulating the immune response affecting the optic nerve or retina of said human, comprising the step of:
- a) administering a therapeutically effective dosage level to said human of said TNF antagonist selected from the group consisting of etanercept, infliximab, CDP571 (a humanized monoclonal anti-TNF-alpha IgG4 antibody), CDP 870 (a humanized monoclonal anti-TNF-alpha antibody fragment) and D2E7 (a human anti-TNF mAb) for treating glaucoma by reducing the inflammation of the optic nerve or retina of said human, or for modulating the immune response affecting the optic nerve or retina of said human.
A method for inhibiting the action of interleukin (IL) for treating neurological disorders in a human by administering an IL Blocker for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human, comprising the step of:
- a) administering a therapeutically effective dosage level to said human of said IL Blocker for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human;
- and
- b) administering said dose either intralesionally or perilesionally.
A method for inhibiting the action of TNF for treating or preventing nerve root injury in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue of said nerve root of said human, or for modulating the immune response affecting neuronal tissue of said nerve root of said human, comprising the steps of:
- a) administering a therapeutically effective dosage level to said human of etanercept, for reducing the inflammation of said nerve root of said human, or for modulating the immune response affecting neuronal tissue of said human;
- and
- b) administering said dose perilesionally by subcutaneous administration in the lumbar area (for lumbar or sacral nerve roots) or in the cervical area (for cervical nerve roots).
A method for inhibiting the action of TNF for treating or preventing nerve root injury in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue of said nerve root of said human, or for modulating the immune response affecting neuronal tissue of said nerve root of said human, comprising the steps of:
- a) administering a therapeutically effective dosage level to said human of D2E7, for reducing the inflammation of said nerve root of said human, or for modulating the immune response affecting neuronal tissue of said human;
- and
- b) administering said dose perilesionally by subcutaneous administration in the lumbar area (for lumbar or sacral nerve roots) or in the cervical area (for cervical nerve roots).
A method for inhibiting the action of TNF for treating or preventing nerve root injury in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue of said nerve root of said human, or for modulating the immune response affecting neuronal tissue of said nerve root of said human, comprising the steps of:
- a) administering a therapeutically effective dosage level to said human of infliximab, for reducing the inflammation of said nerve root of said human, or for modulating the immune response affecting neuronal tissue of said human;
- and
- b) administering said dose perilesionally by subcutaneous administration in the lumbar area (for lumbar or sacral nerve roots) or in the cervical area (for cervical nerve roots).
A method for inhibiting the action of TNF for treating or preventing nerve root injury in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue of said nerve root of said human, or for modulating the immune response to affecting neuronal tissue of said nerve root of said human, comprising the steps of:
- a) administering a therapeutically effective dosage level to said human of CDP 870, for reducing the inflammation of said nerve root of said human, or for modulating the immune response affecting neuronal tissue of said human;
- and
- b) administering said dose perilesionally by subcutaneous administration in the lumbar area (for lumbar or sacral nerve roots) or in the cervical area (for cervical nerve roots).
A method for inhibiting the action of TNF for treating or preventing nerve root injury in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue of said nerve root of said human, or for modulating the immune response affecting neuronal tissue of said nerve root of said human, comprising the steps of:
- a) administering a therapeutically effective dosage level to said human of CDP 571, for reducing the inflammation of said nerve root of said human, or for modulating the immune response affecting neuronal tissue of said human;
- and
- b) administering said dose perilesionally by subcutaneous administration in the lumbar area (for lumbar or sacral nerve roots) or in the cervical area (for cervical nerve roots).
A method for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human, comprising the step of:
- a) administering a therapeutically effective dosage level to said human of said TNF antagonist selected from the group consisting of a fusion protein identified as etanercept, infliximab, CDP57 1 (a humanized monoclonal anti-TNF-alpha IgG4 antibody), CDP 870 (a humanized monoclonal anti-TNF-alpha antibody fragment)and D2E7 (a human anti-TNF mAb) for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human.
Dependencies are inferred from the claim text.